A systematic evidence-based review of treatments for primary hyperhidrosis
- PMID: 33489435
- PMCID: PMC7781989
- DOI: 10.1080/21556660.2020.1857149
A systematic evidence-based review of treatments for primary hyperhidrosis
Abstract
Objective: Hyperhidrosis (excessive sweating) is associated with significant quality-of-life burden yet is often undertreated. With limited FDA-approved treatments, health care providers must determine optimal treatment among approved and off-label options. Key objectives of this review were to reassess, update, and expand a previous systematic review of commonly used treatment options for primary hyperhidrosis, including consideration of aluminum and zirconium compounds.
Methods: We performed a qualitative systematic review of efficacy, health-related quality of life, satisfaction, and safety of interventions, replicating and expanding the strategy outlined in a previous systematic review, with the addition of studies utilizing a within-patient design. We performed a critical appraisal of identified studies to determine risk of bias (RoB) and strength of evidence (SOE).
Results: A total of 32 studies were eligible for critical appraisal. Only three studies - two clinical trials of glycopyrronium cloth (2.4%) and one trial of botulinum toxin A injections in axillary hyperhidrosis were rated as "low" RoB; both had SOE ratings of "moderate" for use in axillary hyperhidrosis - the highest rating included in this review.
Conclusions: Optimal treatment choice depends on several factors, including understanding the quality of evidence regarding each treatment's efficacy and safety (considerations of convenience and cost are beyond the scope of this review). In hyperhidrosis, as in other clinical conditions, treatment decisions should be patient centered. At this time, because of the quality of evidence, only imprecise estimates of effect are possible for hyperhidrosis treatments included in this review, and statements about comparative effectiveness are not possible.
Keywords: Hyperhidrosis; comparative effectiveness; evidence-based; strength of evidence; systematic review; within-patient study design.
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Figures
Similar articles
-
A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis.Am J Clin Dermatol. 2019 Aug;20(4):593-604. doi: 10.1007/s40257-019-00446-6. Am J Clin Dermatol. 2019. PMID: 31111409 Free PMC article. Clinical Trial.
-
Topical Treatment of Primary Focal Hyperhidrosis, Part 1.Int J Pharm Compd. 2019 Jan-Feb;23(1):23-31. Int J Pharm Compd. 2019. PMID: 30668532
-
Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis.Int J Dermatol. 2005 May;44(5):418-24. doi: 10.1111/j.1365-4632.2004.02531.x. Int J Dermatol. 2005. PMID: 15869543 Clinical Trial.
-
Treatment options for hyperhidrosis.Am J Clin Dermatol. 2011 Oct 1;12(5):285-95. doi: 10.2165/11587870-000000000-00000. Am J Clin Dermatol. 2011. PMID: 21714579 Review.
-
Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis.Skin Therapy Lett. 2019 Mar;24(2):1-3. Skin Therapy Lett. 2019. PMID: 30970203 Review.
Cited by
-
Comparison of the Efficacy of Tap Water Iontophoresis Versus Aluminum Chloride Hexahydrate in the Treatment of Palmoplantar Hyperhidrosis.Cureus. 2022 Dec 9;14(12):e32367. doi: 10.7759/cureus.32367. eCollection 2022 Dec. Cureus. 2022. PMID: 36627989 Free PMC article.
-
Recent Developments in Engineering Non-Paralytic Botulinum Molecules for Therapeutic Applications.Toxins (Basel). 2024 Apr 3;16(4):175. doi: 10.3390/toxins16040175. Toxins (Basel). 2024. PMID: 38668600 Free PMC article. Review.
-
The Use of Botulinum Toxin in the Management of Hidradenitis Suppurativa: A Systematic Review.Plast Reconstr Surg Glob Open. 2022 Nov 18;10(11):e4660. doi: 10.1097/GOX.0000000000004660. eCollection 2022 Nov. Plast Reconstr Surg Glob Open. 2022. PMID: 36415615 Free PMC article.
-
Longitudinal Assessment of Facial Hyperhidrosis Management: Evaluating the Utility and Quality of Life Improvements following Botulinum Toxin Injection.Toxins (Basel). 2024 Jan 21;16(1):59. doi: 10.3390/toxins16010059. Toxins (Basel). 2024. PMID: 38276535 Free PMC article.
-
Transfersomal eosin topical delivery assisted by fractional CO2 laser for photodynamic treatment of palmar hyperhidrosis: case study.Drug Deliv Transl Res. 2022 Dec;12(12):3000-3006. doi: 10.1007/s13346-022-01164-z. Epub 2022 Apr 20. Drug Deliv Transl Res. 2022. PMID: 35441986 Free PMC article.
References
-
- Glaser DA, Hebert A, Pieretti L, et al. . Understanding patient experience with hyperhidrosis: a national survey of 1,985 patients. J Drugs Dermatol. 2018;17(4):392–396. - PubMed
-
- Hamm H, Naumann MK, Kowalski JW, et al. . Primary focal hyperhidrosis: disease characteristics and functional impairment. Dermatology. 2006;212(4):343–353. - PubMed
-
- Naumann MK, Hamm H, Lowe NJ.. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol. 2002;147(6):1218–1226. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources